Sp1288

OVERVIEW OF CHRONIC IDIOPATHIC CONSTIPATION: FOCUS ON TREATMENT AND NEW TECHNOLOGY

Date
May 8, 2023

Society: DDW

Chronic constipation affects 11-12% of the world's population. Many food and pharma treatments exist, but choice and timing of therapy can be confusing. Join us to learn more about appropriate use of these treatments and a novel vibrating capsule technology that may improve constipation symptoms via modulation of circadian rhythms. Sponsored by Vibrant Gastro

Tracks

Related Products

Thumbnail for RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RATIONALE: RNA sequencing studies have previously identified impaired barrier function and the subsequent proinflammatory response as critical to the pathogenies of EoE. However, the investigation into disease initiation is often limited by the inability to capture the disease early…
Thumbnail for SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Thumbnail for DISCOVER A DIFFERENT MECHANISM OF ACTION TO TREAT IBS-C: A CASE BASED DISCUSSI
DISCOVER A DIFFERENT MECHANISM OF ACTION TO TREAT IBS-C: A CASE BASED DISCUSSI
Please join us for an engaging discussion led by Dr. Darren Brenner as he shares important clinical considerations in managing patients with IBS-C. The presentation will include interactive patient case studies, along with efficacy and safety data from two phase three clinical trials…
Thumbnail for CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
BACKGROUND: Our previous research has showed that increased sympathetic nervous activity and decreased cannabinoid receptor 1 (CB1) were associated with increased energy expenditure and weight loss following Roux-en-Y gastric bypass (RYGB) in mice…